Antibody infusions vs. antibiotics after CAR-T therapy
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This study compares two ways to help prevent infections after CAR-T cell therapy: regular antibody infusions (immunoglobulins) versus taking antibiotics. If you have low antibody levels after CAR-T treatment, this trial may help decide which approach works better for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 16 and 80 years old.
- You have a type of blood cancer called B-cell acute lymphoblastic leukemia or B-cell lymphoma.
- Your antibody levels (gamma globulins) are low, below 4 g/L, as shown by a blood test.
- You have received or will receive CAR-T cell therapy (a treatment that uses your own immune cells).
- If you could become pregnant, you must agree to use reliable birth control during the study and for 12 months after CAR-T infusion.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether IVIG (a blood product that helps fight infections) can lower infection risk after you receive CD19 CAR-T therapy. It’s meant to help protect you during the vulnerable period after CAR-T treatment.
This trial compares two ways of giving antibiotics to people receiving CAR-T cell therapy for lymphoma or myeloma. It aims to find out whether a more limited antibiotic approach is just as safe and effective as the standard one, possibly reducing side effects.
This trial tests a new type of immune cell therapy (CAR-T) that uses donor cells to target and kill leukemia cells. It is for adults with B-cell acute lymphoblastic leukemia that has not responded to at least two prior treatments.
This trial tests whether a special immune cell therapy (brexucabtagene autoleucel, or CAR T therapy) can help people with B-cell acute lymphocytic leukemia (ALL) after reducing the number of leukemia cells with a chemo-immunotherapy combination. It is for patients whose cancer has returned or is hard to treat, or for those newly diagnosed with a high-risk form of ALL.
This trial checks if giving vaccines after CAR-T cell therapy can help your immune system fight off preventable diseases. It is for adults with certain blood cancers who are about to get CAR-T treatment.
This study tests a new immunoglobulin (antibody) treatment called IgPro20 in adults whose immune systems became weakened after receiving CAR-T cell or TCE therapies for blood cancers. The goal is to help strengthen your immune system and reduce infection risk.
Hear when a new Lymphoma, B-Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.